Evidence map›Paper›PMID 16467915›Full record

ArticleGene therapy & molecular biology2005

Catalytic nucleic acid enzymes for the study and development of therapies in the central nervous system: Review Article.

Richard Tritz, Cellia Habita, Joan M Robbins, German G Gomez, Carol A Kruse

Abstract read
In one paragraph

Article in Gene therapy & molecular biology, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Molecular Testing of Brain Tumor.Journal of pathology and translational medicine · 2017
    Review
  2. FAPP2 gene downregulation increases tumor cell sensitivity to Fas-induced apoptosis.Biochemical and biophysical research communications · 2009
    Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Richard TritzDivision of Cancer Biology, La Jolla Institute for Molecular Medicine, San Diego, CA 92121.
Cellia Habita
Joan M Robbins
German G Gomez
Carol A Kruse

Funding

Proapoptotic Nucleic Acid Agents for Brain Tumor TherapyR21NS056300 · NINDS · SIDNEY KIMMEL CANCER CENTER · PI KRUSE, CAROL A · 2006 to 2007
$533k
ImmunoResistant Brain Tumor ModelsR21NS046463 · NINDS · UNIVERSITY OF COLORADO DENVER · PI KRUSE, CAROL A · 2003 to 2004
$424k
Minority Predoctoral Fellowship ProgramF31CA094834 · NCI · UNIVERSITY OF COLORADO DENVER · PI GOMEZ, GERMAN G · 2001 to 2004
$96k
NCI NIH HHS F31 CA094834NINDS NIH HHS R21 NS046463NINDS NIH HHS R21 NS056300
6 · The paper itself

Abstract

Nucleic acid enzymes have been used with great success for studying natural processes in the central nervous system (CNS). We first provide information on the structural and enzymatic differences of various ribozymes and DNAzymes. We then discuss how they have been used to explore new therapeutic approaches for treating diseases of the CNS. They have been tested in various systems modeling retinitis pigmentosum, proliferative vitreoretinopathy, Alzheimer's disease, and malignant brain tumors. For these models, effective targets for nucleic acid enzymes have been readily identified and the rules for selecting cleavage sites have been well established. The bulk of studies, including those from our laboratory, have emphasized their use for gliomas. With the availability of multiple excellent animal models to test glioma treatments, good progress has been made in the initial testing of nucleic acid enzymes for brain tumor therapy. However, opportunities still exist to significantly improve the delivery and efficacy of ribozymes to achieve effective treatment. The future holds significant potential for the molecular targeting and therapy of eye diseases, neurodegenerative disorders, and brain tumors with these unique treatment agents.

Identifiers

PMID16467915
PMCPMC1351129

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.